Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 12 Best UK Stocks to Buy According to Hedge Funds.
On March 19, 2026, Bernstein initiated coverage of Roivant Sciences Ltd. (NASDAQ:ROIV) with an Outperform rating and a $35 price target, citing potential upside from upcoming clinical readouts in pulmonary hypertension associated with interstitial lung disease and non-infectious uveitis. The firm noted risks around competitive data and launch execution, but said these concerns appear “appropriately discounted.”
Earlier in March, JPMorgan raised its price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $33 from $31 previously and maintained an Overweight rating after updating its model to reflect the company’s settlement with Moderna. JPMorgan described the agreement as a “major overhang lift,” shifting investor focus toward upcoming clinical catalysts.
H.C. Wainwright also raised its price target on Roivant Sciences Ltd. (NASDAQ:ROIV) to $34 from $33 previously and reiterated a Buy rating, incorporating $2.25B in litigation proceeds tied to a global settlement between Roivant subsidiary Genevant Sciences, Arbutus Biopharma, and Moderna related to lipid nanoparticle delivery technology.
Roivant Sciences Ltd. (NASDAQ:ROIV) develops and commercializes biopharmaceutical products across multiple therapeutic areas.
While we acknowledge the potential of ROIV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
